Abstract:We read with interest the study that antibodies induced by receptor binding domain in spike protein of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) do not cross-neutralize Middle East respiratory syndrome coronavirus (MERS-CoV) reported in this journal recently.1Du L. Ma C. Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC.J Infect. 2013; 67: 348-350Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar To date, six CoVs, including human CoV-229E, -NL63, -OC43, -HKU1, SARS-CoV, and MERS-CoV, are known to infect humans. The number of MERS-CoV infection cases in the world has sharply increased since mid-March 2014 and the infections have spread from the Middle East to Europe, North Africa, Asia, and America. The World Health Organization (WHO) has encouraged all countries to monitor MRES-CoV and to carefully review any unusual patterns. However, for mild or unusual symptomatic infection, it is not always possible to identify the infection with MERS-CoV using PCR assay. Hence, it is important to perform seroepidemiological studies in natural populations to analyze HCoVs' epidemiologic spectrum. The CoV nuleocapide (N) protein is abundantly produced during infection and exhibits strong immunogenicity, which can act as an ideal antigen for viral antibody detection.2Lai M.M.C. Perlman S. Anderson L.J. Coronaviridae.in: 5th ed. Fields virology. vol. 1. Lippincott Williams & Wilkins, Philadelphia2007: 1306-1336Google Scholar, 3Timani K.A. Ye L. Ye L. Zhu Y. Wu Z. Gong Z. Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS.J Clin Virol. 2004; 30: 309-312Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar, 4Sastre P. Dijkman R. Camuñas A. Ruiz T. Jebbink M.F. van der Hoek L. et al.Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies.Clin Vaccin Immunol. 2011; 18: 113-118Crossref PubMed Scopus (31) Google Scholar However, the antigenic and serologic relationship between N proteins within subgroups of the six HCoVs, such as NL63 and 229E (both subgroup 1b), OC43 and HKU1 (both subgroup 2a), has not been fully understood, which can affect seropositive data of HCoVs. A recent study showed that BtCoV HKU5 and BtCoV HKU4 N proteins within the 2c subgroups share cross-reactive epitopes with MERS-CoV. In addition, BtCoV HKU3 and BtCoV 279 N proteins within the 2b subgroups share cross-reactive epitopes with SARS-CoV.5Agnihothram S. Gopal R. Yount Jr., B.L. Donaldson E.F. Menachery V.D. Graham R.L. et al.Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.J Infect Dis. 2014; 209: 995-1006Crossref PubMed Scopus (84) Google Scholar To evaluate the cross-reactivities among HCoVs, we developed a competitive ELISA (cELISA) as previously described for detecting anti-N IgG antibodies of six HCoVs.6Guo L. Wang Y. Zhou H. Wu C. Song J. Li J. et al.Differential seroprevalence of human bocavirus species 1-4 in Beijing, China.PLoS One. 2012; 7: e39644Crossref PubMed Scopus (33) Google Scholar To this end, we first identify HCoV-positive (including HCoV-229E, -OC43 -NL63, -HKU1, and SARS-CoV) and -negative human serum samples by Western blot analysis. Using these positive controls, we found that 1.0 μg/ml of competing N protein was sufficient for the competition assays in cELISA (Fig. 1A–E). We then evaluated the possible cross-reactivity among N proteins using cELISA with the positive control sera. Our results suggest that HCoV-229E and -NL63 (subgroup 1b), and HCoV-OC43 and -HKU1 (subgroup 2a) share subgroup cross-reactive epitopes among their N proteins (Fig. 1A–E). However, no cross-reactivity was observed between the N proteins across groups or subgroups. Therefore, cELISA assays were performed with N proteins between HCoV-NL63 and -229E, and HCoV-OC43 and -HKU1 to minimize the cross-reactivity for seroprevalence determination. Since we did not have access to the positive human serum against MERS-CoV, the cross-reactivity of MERS-CoV antibodies with other HCoV N proteins could not be determined. We performed cELISA of MERS-CoV competing with the other five N proteins together. To evaluate the seroprevalence of HCoVs in China, we determined the cut-off values of the cELISA for six HCoVs as previously described.7Kean J.M. Rao S. Wang M. Garcea R.L. Seroepidemiology of human polyomaviruses.PLoS Pathog. 2009; 5: e1000363Crossref PubMed Scopus (594) Google Scholar, 8Hustedt J.W. Christie C. Hustedt M.M. Esposito D. Vazquez M. Seroepidemiology of human bocavirus infection in Jamaica.PLoS One. 2012; 7: e38206Crossref PubMed Scopus (22) Google Scholar We obtained the cut-off values of HCoV-NL63, -229E, -OC43, -HKU1, SARS-CoV, and MERS-CoV as 0.25, 0.25, 0.23, 0.25, 0.27, and 0.25, respectively. A tested sample was considered positive if its A450 was above the cut-off value. Then we tested anti-N IgG in sera from 695 healthy adults ≥15 yr by cELISA (Fig. 1F). We obtained seroprevalences of 50.8% for HCoV-229E, 67.1% for -NL63, 70.8% for -OC43, and 25.6.7% for -HKU1 for the age group of 15–44 year olds. Seroprevalences decreased with age, with 10.7% for HCoV-229E, 25.2% for -NL63, 40.3% for -OC43, and 14.5% for -HKU1 for old adults of ≥60 yr. No SARS-CoV and MERS-CoV IgG were detected in these serum samples. The seropositive rates of HCoV-NL63 and -OC43 were higher than those of HCoV-229E and -HKU1 (χ2 tests. χ2 = 130.8, P = 3.9 × 10−29 for HCoV-NL63 vs -229E and -HKU1; χ2 = 239, P = 1.2 × 10−52 for HCoV-OC43 vs -229E and -HKU1) (Fig. 1F). Our data suggest that there is an age-related waning of HCoV-229E, -NL63, -OC43, and -HKU1 specific antibodies. The seroprevalence of 492 healthy children ≤14 yr were 12.4% for HCoV-229E, 33.7% for -NL63, 32.5% for -OC43, 15.4% for -HKU1, 0% for SARS-CoV, and 0% for MERS-CoV IgG (Fig. 1F). Anti-N-IgG antibodies of HCoV-229E, -NL63, -OC43, and -HKU1 were detected in children between 0.5 and 2 yr in this study population, suggesting that exposure to HCoV-229E, -NL63, -OC43, and -HKU1 may occur early in childhood. To assess the relationship between anti-N-IgG and HCoV infection, we measured the IgG antibody in 361 serum samples from children with lower respiratory infections (Table 1). Of 246 samples from HCoV-negative patients, 124 (50.4%) had serologic evidence for past exposure of HCoV-229E, 142 (57.7%) for -NL63, 123 (50%) for -OC43, and 133 (54.1%) for -HKU1. However, among the 30 children who were HCoV-NL63-positive, only 7 (23.3%) were seropositive for anti-N-IgG. Similar results were found in serum samples from those who were positive for HCoV-NL63 (23.8%), -OC43 (18.4%), and -HKU1 (23.1%). Further analysis showed that IgG seropositive rates of HCoV-negative patients were significantly higher than those from HCoV-positive patients (χ2 tests. χ2 = 7.68, P = 0.0056 for HCoV-NL63; χ2 = 6.81, P = 0.00906 for HCoV-229E; χ2 = 11.98, P = 0.00054 for HCoV-OC43; χ2 = 7.84, P = 0.00511 for HCoV-HKU1), suggesting that the low anti-N IgG level may be used as a predictive index for susceptibility to HCoV in a population.Table 1Comparison of serum IgG antibody levels against N proteins for ARTI patients positive and negative for HCoVs.HCoVsPositiveNegativeχ2, P valueAllIgG+ (%)IgG− (%)AllIgG+ (%)IgG− (%)NL63215aNumber of positive samples.(23.8)bPercentage of positive samples.16 (76.2)246142 (57.7)104 (42.3)χ2 = 7.68, P = 0.0056229E307 (23.3)23 (76.7)246124 (50.4)122 (49.6)χ2 = 6.81, P = 0.00906OC43387 (18.4)31 (81.6)246123 (50.0)123 (50.0)χ2 = 11.98, P = 0.00054HKU1266 (23.1)20 (76.9)246133 (54.1)113 (45.9)χ2 = 7.84, P = 0.00511a Number of positive samples.b Percentage of positive samples. Open table in a new tab In summary, our results suggest that the development of specific serologic diagnosis for HCoVs infection based on N proteins needs to take into consideration the cross-reactivities existing in the same subgroup. However, a common diagnostic platform for HCoVs should include a panel of phylogenetically distinct N proteins. Further, the anti-N IgG may serve as an indication of susceptibility to HCoV infections. Our study is informative for developing HCoV immunoassays and provides insights into the prevalence and pathologic roles of HCoVs. No reported conflicts. We thank the Beijing Children's Hospital, Beijing Blood Center, and Shandong Medicinal Biotechnology Center for providing blood samples. This study was supported in part by the Chinese National Major S & T Project (2012ZX10004-206, 2014ZX10004-001), the National Foundation for Distinguished Young Scientists (81225014), the Program for Changjiang Scholars and Innovative Research Team in University (IRT13007) and the Fondation Mérieux.

Abstract:The novel coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The lack of targeted molecular therapy for patients with SARS-CoV-2 infection has led to high mortality.1Vabret N. Britton G.J. Gruber C. Hegde S. Kim J. Kuksin M. Levantovsky R. Malle L. Moreira A. Park M.D. et al.Sinai Immunology Review ProjectImmunology of COVID-19: current state of the science.Immunity. 2020; 52: 910-941Abstract Full Text Full Text PDF PubMed Scopus (1087) Google Scholar The study of pre-existing cross-reacting immunity to pre- and post-pandemic coronaviruses provides direction for the development of targeted molecular therapy for members of this class of virus.2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar, 3Lv H. Wu N.C. Tsang O.T. Yuan M. Perera R.A.P.M. Leung W.S. So R.T.Y. Chan J.M.C. Yip G.K. Chik T.S.H. et al.Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Rep. 2020; 31: 107725Abstract Full Text Full Text PDF PubMed Scopus (249) Google Scholar, 4Yuan M. Wu N.C. Zhu X. Lee C.D. So R.T.Y. Lv H. Mok C.K.P. Wilson I.A. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.Science. 2020; 368: 630-633Crossref PubMed Scopus (939) Google Scholar, 5Pinto D. Park Y.J. Beltramello M. Walls A.C. Tortorici M.A. Bianchi S. Jaconi S. Culap K. Zatta F. De Marco A. et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature. 2020; 583: 290-295Crossref PubMed Scopus (1086) Google Scholar, 6Baum A. Fulton B.O. Wloga E. Copin R. Pascal K.E. Russo V. Giordano S. Lanza K. Negron N. Ni M. et al.Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.Science. 2020; 369: 1014-1018Crossref PubMed Scopus (816) Google Scholar Combining two or more anti-SARS-CoV-2 spike receptor binding domain (RBD) antibodies should strengthen SARS-CoV-2 neutralization and might restrict the generation of neutralization-evading mutants. Coronaviruses are a group of single-stranded RNA-enveloped viruses that infect the respiratory tract, with some species causing severe acute respiratory syndrome (SARS). SARS-CoV-2 is the causative pathogen of the ongoing COVID-19 pandemic.1Vabret N. Britton G.J. Gruber C. Hegde S. Kim J. Kuksin M. Levantovsky R. Malle L. Moreira A. Park M.D. et al.Sinai Immunology Review ProjectImmunology of COVID-19: current state of the science.Immunity. 2020; 52: 910-941Abstract Full Text Full Text PDF PubMed Scopus (1087) Google Scholar The membrane surface of SARS-CoV-2 is covered by spike proteins, which are comprised of 1273 amino acids (aa), including an N-terminal signal peptide (aa 1–13), an S1 subunit (aa 14–685; Figure 1), and an S2 subunit (aa 686–1273; Figure 1). The S1 subunit is composed of an N-terminal domain (aa 14–305) and an RBD motif (aa 319–541) that binds to the host cell receptor, angiotensin-converting enzyme 2 (ACE2), to mediate entry into epithelial cells of the lung.1Vabret N. Britton G.J. Gruber C. Hegde S. Kim J. Kuksin M. Levantovsky R. Malle L. Moreira A. Park M.D. et al.Sinai Immunology Review ProjectImmunology of COVID-19: current state of the science.Immunity. 2020; 52: 910-941Abstract Full Text Full Text PDF PubMed Scopus (1087) Google Scholar Phylogenetic analysis of full-length genome sequences obtained from infected patients showed that SARS-CoV-2 is similar to the originally described SARS-CoV, which caused an outbreak of SARS in Asia in 2003, and uses the same cell entry receptor. The RBD region is a critical target for neutralizing antibodies, and SARS-CoV-2 and SARS-CoV RBDs are ~75% similar in sequence.1Vabret N. Britton G.J. Gruber C. Hegde S. Kim J. Kuksin M. Levantovsky R. Malle L. Moreira A. Park M.D. et al.Sinai Immunology Review ProjectImmunology of COVID-19: current state of the science.Immunity. 2020; 52: 910-941Abstract Full Text Full Text PDF PubMed Scopus (1087) Google Scholar,2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar Four known seasonal "common cold" human coronaviruses (HCoVs), namely HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E, cause human upper respiratory tract infections annually.2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar Grifoni and colleagues2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar investigated serum from donors sampled in 2015 and 2018 and who had not been exposed to SARS-CoV-2. All of these donors were positive for HCoV-OC43 and HCoV-NL63, as assessed by an immunoglobulin G (IgG) ELISA test for reactivity to the corresponding spike RBDs. Approximately 40%–60% of these SARS-CoV-2-unexposed individuals exhibited SARS-CoV-2-reactive non-spike-specific CD4+ T cells upon stimulation with SARS-CoV-2 non-spike peptide pools. These results suggest that there is pre-existing SARS-CoV-2 non-spike-specific immunity in people infected by seasonal "common cold" HCoV-OC43 and HCoV-NL63 viruses. This pre-existing SARS-CoV-2-specific immunity might reduce the severity of subsequent infection with the latter.2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar Further studies showed that although antibody cross-reactivity appears relatively common, cross-neutralization reactions may be rare. Lv and colleagues3Lv H. Wu N.C. Tsang O.T. Yuan M. Perera R.A.P.M. Leung W.S. So R.T.Y. Chan J.M.C. Yip G.K. Chik T.S.H. et al.Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Rep. 2020; 31: 107725Abstract Full Text Full Text PDF PubMed Scopus (249) Google Scholar reported that plasma samples from 15 patients with COVID-19 showed significant cross-reactivity to the SARS-CoV spike non-RBD, and 5 of the 15 samples showed convincing cross-reactivity with SARS-CoV RBD. However, only 1 of the 15 samples could weakly cross-neutralize SARS-CoV. The authors also reported plasma samples from 7 patients with SARS that could significantly cross-react with both SARS-CoV-2 spike non-RBD and spike RBD, although none of these plasma samples were able to cross-neutralize SARS-CoV-2. These findings indicate that infection by one subtype of coronavirus induces antibodies that can bind to the non-RBD and RBD regions of the spike protein on other subtypes of coronavirus.2Grifoni A. Weiskopf D. Ramirez S.I. Mateus J. Dan J.M. Moderbacher C.R. Rawlings S.A. Sutherland A. Premkumar L. Jadi R.S. et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.Cell. 2020; 181: 1489-1501.e15Abstract Full Text Full Text PDF PubMed Scopus (2357) Google Scholar,3Lv H. Wu N.C. Tsang O.T. Yuan M. Perera R.A.P.M. Leung W.S. So R.T.Y. Chan J.M.C. Yip G.K. Chik T.S.H. et al.Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Rep. 2020; 31: 107725Abstract Full Text Full Text PDF PubMed Scopus (249) Google Scholar Yuan and colleagues4Yuan M. Wu N.C. Zhu X. Lee C.D. So R.T.Y. Lv H. Mok C.K.P. Wilson I.A. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.Science. 2020; 368: 630-633Crossref PubMed Scopus (939) Google Scholar recently described a neutralizing monoclonal antibody (mAb; CR3022) previously isolated from a convalescent SARS patient that could bind the RBD of the SARS-CoV-2 spike protein. Other recent studies have shown that this cross-reactive antibody has relatively strong binding affinity to SARS-CoV-2. CR3022 targets a highly conserved cryptic epitope in the RBD, which enables cross-reactive binding to both the SARS-CoV-2 and SARS-CoV RBDs. A key finding is that the antibody binding sites in the two coronaviruses are very similar, differing by only 4 amino acids. This high degree of similarity suggests that this site within the RBD contains an important viral function that could be lost if the site underwent significant mutations. The fact that the mAb binding site is highly conserved between SARS-CoV and SARS-CoV-2 also indicates that antibodies yet to be identified might effectively neutralize both viruses and prevent a pandemic in the future.4Yuan M. Wu N.C. Zhu X. Lee C.D. So R.T.Y. Lv H. Mok C.K.P. Wilson I.A. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.Science. 2020; 368: 630-633Crossref PubMed Scopus (939) Google Scholar Pinto and colleagues5Pinto D. Park Y.J. Beltramello M. Walls A.C. Tortorici M.A. Bianchi S. Jaconi S. Culap K. Zatta F. De Marco A. et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature. 2020; 583: 290-295Crossref PubMed Scopus (1086) Google Scholar reported another neutralizing mAb (S309) isolated from a convalescent SARS patient. This antibody also bound the previously mentioned conserved area of the RBD (17 out of 22 residues of the epitope) of SARS-CoV and SARS-CoV-2. Importantly, the data showed that S309 could neutralize potentially 11,839 SARS-CoV-2 isolates known, to date, to be circulating. However, S309 IgG-mediated neutralization reached 100%, whereas neutralization plateaued at approximately 80% in the presence of S309 Fab. This result indicates that one or more IgG-specific bivalent mechanisms—such as S-glycoprotein trimer cross-linking, steric hindrance, aggregation of virions, or antibody-dependent cell cytotoxicity—may contribute to the ability of S309 to fully neutralize pseudovirions. Furthermore, S309 could recruit effector mechanisms, and showed increased neutralization of other weakly neutralizing mAbs in combination with such a neutralizing mAb, which may reduce the risk of viral escape.5Pinto D. Park Y.J. Beltramello M. Walls A.C. Tortorici M.A. Bianchi S. Jaconi S. Culap K. Zatta F. De Marco A. et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature. 2020; 583: 290-295Crossref PubMed Scopus (1086) Google Scholar Antibodies of different isotypes activate different effector mechanisms in response to antigens. Therefore, a combination of IgG1 and IgG2 isotypes against the same antigen may enhance this effect. Baum and colleagues6Baum A. Fulton B.O. Wloga E. Copin R. Pascal K.E. Russo V. Giordano S. Lanza K. Negron N. Ni M. et al.Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.Science. 2020; 369: 1014-1018Crossref PubMed Scopus (816) Google Scholar reported the important finding that 2 antibodies binding distinct and non-overlapping regions of the RBD could concurrently bind and block RBD function (Figure 1). The authors demonstrated that growing a pseudovirus in the presence of any one of these two antibodies led to the development of spike mutants with resistance to the antibody. In contrast, escape mutants did not develop when the pseudovirus was cultured in the presence of pairs of antibodies that either do not compete or only partially compete for binding to the RBD. The discovery of spike protein cross-reactivity provides direction for future research. The combination of 2 or more anti-SARS-CoV-2 spike RBD antibodies should strengthen SARS-CoV-2 neutralization and may restrict the generation of neutralization-evading mutants.5Pinto D. Park Y.J. Beltramello M. Walls A.C. Tortorici M.A. Bianchi S. Jaconi S. Culap K. Zatta F. De Marco A. et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature. 2020; 583: 290-295Crossref PubMed Scopus (1086) Google Scholar,6Baum A. Fulton B.O. Wloga E. Copin R. Pascal K.E. Russo V. Giordano S. Lanza K. Negron N. Ni M. et al.Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.Science. 2020; 369: 1014-1018Crossref PubMed Scopus (816) Google Scholar Although no clinical trials have yet been reported, SARS-CoV-2-neutralizing mAb combination therapy might prove beneficial to curb pandemics in the future. The authors declare no competing interests. Q.Z., G.H., and Y.L. contributed equally to this article and share first authorship. Address reprint requests and correspondence to Y.X. at [email protected].

Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates with Disease Severity in COVID-19 Patients: a Retrospective Study.

Antibody Against Nucleocapsid Protein Predicts Susceptibility to Human Coronavirus Infection

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients

A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.

Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Human Post‐infection Serological Response to the Spike and Nucleocapsid Proteins of SARS‐CoV‐2

Clinical and Antibody Characteristics Reveal Diverse Signatures of Severe and Non-severe SARS-CoV-2 Patients

Serum Inflammatory Factors Are Positively Correlated with the Production of Specific Antibodies in Coronavirus Disease 2019 Patients

Seropositive Reaction Rates of 9 B-Cell Epitopes of the SARS-CoV-2 Spike Protein and the Relationship between the Epitopes and Neutralizing Antibody

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination

The kinetics of humoral response and its relationship with the disease severity in COVID-19

Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients

Epidemiological and Co-Infection Characteristics of Common Human Coronaviruses in Shanghai, 2015–2020: a Retrospective Observational Study

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19

Sars-Cov-2 Antibodies And Associated Factors At Different Hospitalization Time Points In 192 Covid-19 Cases

Human coronavirus OC43 and its correlation with SARS-CoV-2